Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders

Revue Neurologique

Volumn 174, Issue 4, 2018, Pages 255-264

  Ciron, J ^a,b   Audoin, B ^c,d   Bourre, B ^e   Brassat, D ^a,f   Durand Dubief, F ^g   Laplaud, D ^h   Maillart, E ⁱ   Papeix, C ⁱ   Vukusic, S ^g,j,k   Zephir, H ^l   Marignier, R ^g,j   Collongues, N ^m  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c TIMONE HOSPITAL   (France)

^d University of Aix Marseille   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f France   (France)

^g HÔPITAL NEUROLOGIQUE   (France)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j LYON NEUROSCIENCE RESEARCH CENTER   (France)

^k UNIVERSITÉ LYON 1   (France)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF STRASBOURG   (France)

more..

Author keywords

Guidelines; Neuromyelitis optica; Recommendations; Rituximab; Treatment

Indexed keywords

CD20 ANTIGEN; RITUXIMAB; MONOCLONAL ANTIBODY;

ARTICLE; BREAST FEEDING; DRUG DOSE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; MYELOOPTIC NEUROPATHY; PATERNAL EXPOSURE; PRACTICE GUIDELINE; PREGNANCY; RISK FACTOR; THERAPEUTIC ABORTION; TREATMENT OUTCOME; VACCINATION;

ANTIBODIES, MONOCLONAL; HUMANS; NEUROMYELITIS OPTICA; PRACTICE GUIDELINES AS TOPIC; RITUXIMAB;

EID: 85045011269     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2017.11.005     Document Type: Article

References (44)

1. Wingerchuk, D.M., et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 (2015), 177–189.
2. Collongues, N., de Seze, J., An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord 9 (2016), 180–188.
3. Zéphir, H., et al. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol 262 (2015), 2329–2335.
4. Collongues, N., et al. Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler 22 (2016), 955–959.
5. van Vollenhoven, R.F., et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72 (2013), 1496–1502.
6. Burr, M.L., Malaviya, A.P., Gaston, J.H., Carmichael, A.J., Ostör, A.J.K., Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology 47 (2008), 738–739.
7. Club Rhumatismes et Inflammation. Fiches pratiques. Prise en charge pratique des patients sous Rituximab. Que faire en cas d'antécédent ou d'apparition d'infections bactériennes et virales. Available at: http://www.cri-net.com.
8. Haut Conseil de la Santé Publique. Vaccinations des personnes immunodéprimées ou aspléniques. Recommandations.
9. Haut Conseil de la Santé Publique. Avis relatif aux recommandations vaccinales contre les infections à pneumocoque pour les adultes.
10. Aksoy, S., et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48 (2007), 1307–1312.
11. Hawker, K., et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66 (2009), 460–471.
12. Annovazzi, P., et al. Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. J Neurol 263 (2016), 1727–1735.
13. Kim, S.-H., Kim, W., Li, X.F., Jung, I.-J., Kim, H.J., Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68 (2011), 1412–1420.
14. Kim, S.-H., Huh, S.-Y., Lee, S.J., Joung, A., Kim, H.J., A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70 (2013), 1110–1117.
15. Kim, S.-H., et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of fcgr3a polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72 (2015), 989–995.
16. Smolen, J.S., et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007), 143–150.
17. Emery, P., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006), 1390–1400.
18. Damato, V., Evoli, A., Iorio, R., Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 73 (2016), 1342–1348.
19. Mease, P.J., et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the dose-ranging assessment: international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) trial. J Rheumatol 35 (2008), 20–30.
20. Pellkofer, H.L., et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76 (2011), 1310–1315.
21. Mealy, M.A., Wingerchuk, D.M., Palace, J., Greenberg, B.M., Levy, M., Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71 (2014), 324–330.
22. Lebrun, C., et al. Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis. J Neuroimmunol 298 (2016), 79–81.
23. Cohen, M., et al. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study. J Neurol Sci 373 (2017), 335–338.
24. Jarius, S., et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain J Neurol 131 (2008), 3072–3080.
25. Chanson, J.-B., et al. Evaluation of clinical interest of anti-aquaporin-4 autoantibody follow-up in neuromyelitis optica. Clin Dev Immunol, 2013, 2013, 146219.
26. Chanson, J.-B., de Seze, J., Eliaou, J.-F., Vincent, T., Immunological follow-up of patients with neuromyelitis optica: is there a good biomarker?. Lupus 22 (2013), 229–232.
27. Valentino, P., Marnetto, F., Granieri, L., Capobianco, M., Bertolotto, A., Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study. Neurol Neuroimmunol Neuroinflammation, 4, 2017, e317.
28. Hennes, E.-M., et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89 (2017), 900–908, 10.1212/WNL.0000000000004312.
29. Thurlings, R.M., et al. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 69 (2010), 409–412.
30. Yang, C.-S., et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81 (2013), 710–713.
31. Chay, J., Donovan, P., Cummins, L., Kubler, P., Pillans, P., Experience with low-dose rituximab in off-label indications at two tertiary hospitals. Intern Med J 43 (2013), 871–882.
32. Bourre, B., et al. Neuromyelitis optica and pregnancy. Neurology 78 (2012), 875–879.
33. Kim, W., et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology 78 (2012), 1264–1267.
34. Fragoso, Y.D., et al. Neuromyelitis optica and pregnancy. J Neurol 260 (2013), 2614–2619.
35. Shimizu, Y., et al. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder. Mult Scler 22 (2016), 1413–1420.
36. Nour, M.M., et al. Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology 86 (2016), 79–87.
37. Huang, Y., et al. Pregnancy in neuromyelitis optica spectrum disorder: A multicenter study from South China. J Neurol Sci 372 (2017), 152–156.
38. Boye, J., Elter, T., Engert, A., An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14 (2003), 520–535.
39. Chakravarty, E.F., Murray, E.R., Kelman, A., Farmer, P., Pregnancy outcomes after maternal exposure to rituximab. Blood 117 (2011), 1499–1506.
40. De Cock, D., et al. Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. Rheumatology 56 (2017), 661–663.
41. Pellkofer, H.L., Suessmair, C., Schulze, A., Hohlfeld, R., Kuempfel, T., Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler 15 (2009), 1006–1008.
42. Ringelstein, M., et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler 19 (2013), 1544–1547.
43. Vukusic, S., Marignier, R., Multiple sclerosis and pregnancy in the “treatment era”. Nat Rev Neurol 11 (2015), 280–289.
44. Bragnes, Y., Boshuizen, R., de Vries, A., Lexberg, Å., Østensen, M., Low level of Rituximab in human breast milk in a patient treated during lactation. Rheumatology 56 (2017), 1047–1048.